Nanobiotix JNJ-1900 Study Yields Promising Results for Non-Small Cell Lung Cancer Patients

Nanobiotix, a company focused on cancer treatment, has announced updated safety and efficacy data from its JNJ-1900 study. The data shows that the treatment was well-tolerated by patients with non-small cell lung cancer (NSCLC) and achieved significant results in terms of tumor response.

The updated data is based on a preliminary analysis of 44 patients who received JNJ-1900 as part of the ongoing phase II study. The results indicate that 50% of patients experienced a partial or complete tumor response, with some patients achieving a durable response lasting up to six months.

Nanobiotix's CEO, Laurent Levy, emphasized the importance of this data in a statement, saying 'These preliminary results demonstrate the potential of JNJ-1900 to provide meaningful therapeutic benefits for patients with NSCLC.'